The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://donnawcea038340.wikipowell.com/6761258/retatrutide_vs_tirzepatide_a_comparative_analysis